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Abstract 
Purpose: To investigate the effect of withaferin A on tumor growth and metastasis in liver in a nude 
mouse model.  
Methods: Withaferin A was injected through a portal vein to the orthotopic liver tumor in a nude mice 
model. Xenogen in vivo imaging system was used to monitor tumor growth and metastasis. The effect 
of withaferin A on tumor volume, invasive growth pattern, expression of Pyk2, upregulation of BAX/P53, 
apoptotic signaling and ROCK/IP10/VEGF pathway along with cytoskeletal protein actin projection 
formation was studied. Tumor/non-tumor margin was examined under electron microscopy. In addition, 
the direct effect of withaferin A on liver cancer cells and endothelial cells was further investigated. 
Results: A significant inhibition of tumor growth and lower incidence of lung metastasis was observed 
after withaferin A treatment. Withaferin A treatment led to a decrease in the incidence of intrahepatic 
metastasis from 90 (9 of 10) to 10 % (1 of 10, p = 0.041). There was decrease in macrophage infiltration 
in the liver tumors and vessels. Western blot analysis revealed inhibition of expression of Pyk2, ROCK1 
protein and VEGF. Electron microscopy showed tumor vascular endothelial cell damage and significant 
necrosis of tumor tissues. It also suppressed formation of cytoskeletal protein actin projection involved 
in cell migration. 
Conclusion: Withaferin A inhibits liver tumor invasion and angiogenesis by downregulation of cell 
signalling pathway leading to invasion and angiogenesis. Therefore, withaferin A is a promising 
candidate for the treatment of liver tumor invasion and angiogenesis. 
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Due to difficulty in detection, aggressive and 
chemoresistant behaviour of metastatic cells no 
efficient treatments are available for metastatic 
disease [1]. Invasion of tumor cells into 
surrounding tissue, intravasation into blood or 
lymphatic vessels and extravasation into new 
host environment are triggered by a process 
termed as epithelial mesenchymal transition 
(EMT) [2,3]. It is reported that cancer cells can 
re-trigger EMT to migrate into surrounding tissue 
[3,4]. Rho kinase (ROCK) plays a significant role 
in regulating cytoskeletal events and invasion of 
hepatocellular carcinoma [5,6]. It is believed that 
IFN-inducible protein 10 (IP10) which promotes 
tumor cell invasiveness in colon cancer [7] and is 
related to angiogenesis in uterine cervical 
cancers [8] has key role in hepatocellular 
carcinoma invasiveness. Vascular endothelial 
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growth factor (VEGF) and matrix 
metalloproteinase 9 (MMP9) secreted by 
macrophages promote tumor invasion and 
angiogenesis [9,10]. Angiopoietins in the 
presence of VEGF may promote tumor 
angiogenesis and progression in human 
hepatocellular carcinoma [11].  
 
Withaferin A (1), a steroidal lactone is isolated 
from Withania somnifera, the extracts of which 
are used in traditional East Indian medicine [12]. 
Out of 14 withanolides isolated from W. 
somnifera, withaferin A is present as a major 
compound [13,14]. Withaferin A has anti-
angiogenic effect [12,15] at micromolar doses 
and inhibits soft tissue sarcoma growth and local 
recurrence in xenograft experiments [16]. It is 
reported to have proapoptotic and anti-tumor 
activity in breast and prostate cancers [17-19]. 
Withaferin A acts on NF-Kb, BCL-2, FOXO3A, 
Hsp90, phosphorylated STAT3 and annexin II 
[18,20-24].  
 
Taking cue from the literature, we designed an 
experiment to study the effect of withaferin A on 
suppression of liver tumor growth in a nude 
mouse model with an attempt to develop a potent 










Human hepatocellular carcinoma cell lines 
MHCC97 and JHH-5 were maintained in DMEM 
with high glucose (Life Technologies) 
supplemented with 10 % heat-inactivated fetal 
bovine serum (Life Technologies), 100 mg/mL 
penicillin G, and 50 μg/mL streptomycin (Life 
Technologies) at 37 °C in a humidified 
atmosphere containing 5 % CO2.  
 
Orthotopic nude mice liver tumor model 
 
MHCC97 cells (6 × 105) were cultured in culture 
medium and harvested. After cell viability was 
determined, 2 x 106 viable cells were injected 
subcutaneously at the proximal dorsal midline of 
6-week-old male athymic nu/nu mice (Harlan). 
The tumors were removed after attaining 0.8 to 1 
cm diameter, cut into cubes of 1 to 2 mm3 in size, 
which were then implanted into the left liver lobes 
of another group of nude mice. The study was 
approved by the institutional committee for 
animal care and use.  
 
Treatment, imaging, and sample collection 
 
Withaferin A (withaferin A, treatment group) or 
phosphate-buffered saline (PBS) solution (control 
group) was injected via the portal vein after 
tumor implantation. Blood samples were 
collected every week from the tail vein for the 
detection of serum levels of withaferin A. Mice 
bearing liver tumors were checked by a higher-
resolution 7T magnetic resonance imaging 
scanner, PharmaScan 70/16 (Bruker BioSpin). 
Liver tumor growth and lung metastasis were 
monitored by Xenogen IVIS every week. The 
nude mice were sacrificed at weeks 4, 5, and 6, 
respectively, after tumor implantation. Liver, lung, 
kidney, and spleen suspected of tumor 
metastasis were sampled for tissue sectioning to 
examine intrahepatic, lung, kidney, and spleen 
metastases. 
 
Light and transmission electron microscopy 
 
Tumor tissues in liver were collected for light 
microscopy with H&E staining at different time 
points after tumor implantation. The specimens 
were immediately cut into 1-mm cubes and fixed 
in 2.5 % glutaraldehyde in sodium carcodylate 
hydrochloride buffer overnight at 4 °C for 
electron microscopy section. The sections were 
then examined under a transmission electron 
microscope, Philips EM 208 (Koninklijke Philips 
Electronics, Eindhoven, Netherlands). 
 
Gene expression of ROCK1, IP10, and MMP9 
 
Total RNA (0.5 μg) isolated from liver tumor cells 
using RNeasy Midi kit (Qiagen) was subjected to 
reverse transcription reaction using TaqMan 
Reverse Transcription Reagents (ref. 24; Applied 
Biosystems). The product (1 μL) was used to 
perform real-time quantitative reverse 
transcription-PCR using TaqMan Core Reagent 
kit (Applied Biosystems). The ABI PRISM 
7900HT Sequence Detection System (PE 
Applied Biosystems) was used for real-time 
cDNA quantitation of ROCK, IP10, angiopoietin 
1, and VEGF.  
 
The primer sets and probes were also purchased 
from Applied Biosystems. Human GAPDH was 
used as an endogenous control (TaqMan human 
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GAPDH Control Reagents kit, Applied 
Biosystems). The 2-ΔΔCt method was used to 
calculate the relative fold difference of ROCK, 
IP10, angiopoietin 1, and VEGF expressions in 
all samples. 
 
Western blot analysis 
 
Proteins were isolated with IP buffer, and total 
protein concentration was determined using the 
Bio-Rad (Hercules, CA) assay. Total protein (50 
μg) were loaded per well. Blotted membranes 
were incubated with primary antibody. Anti–
ROCK-1, anti-0IP10, and anti-VEGF antibodies 
were purchased from BD Biosciences, San Jose, 
CA. Anti-Akt, anti–phospho-Akt (Ser473), anti–
Bcl-2, anti-BAX, and anti–phospho-p53 (Ser15) 
antibodies were from Cell Signaling Technology. 
 
Liquefied matrigel assay for tube formation 
 
MHCC97 cells (1 x 105) were seeded in Liquefied 
Matrigel (BD Biosciences) precoated 96-well 
plate. Withaferin A was added to the wells at a 
dose of 50 μg/mL. Digital camera was used to 




All data represent the mean of three independent 
experiments. The significance of differences 
between means was determined by Student's t-





Effect of withaferin A on liver tumor growth 
and metastasis 
 
To determine the effect of withaferin A treatment 
on tumor volume, orthotopic tumor implantation 
was followed by measurement of tumor volume 
after 4, 5, and 6 weeks (Fig. 2A and B; Table 1). 
A decrease in incidence of intrahepatic 
metastasis was observed from 90 % (9 of 10) to 
10 % after withaferin A treatment. There was 
also suppression in lung metastasis on treatment 
with withaferin A. Incidence of lung metastasis in 




Table 1: Comparison of tumor volume from mice with or without withaferin A treatment 
 
Duration after tumor implantation Treatment 
(n = 10) 
Control 
(n = 10) 
P-value 
4 wk, volume of tumor (mm3) 16.87  1122 0.005 
5 wk, tumor volume (mm3) 72.33 1,267 0.004 
6 wk, tumor volume (mm3) 62 2,640 0.004 




Fig. 2: The effect of withaferin A on in vivo tumor growth and metastasis of HCC. Withaferin A treatment 
suppressed tumor growth and metastasis in subcutaneous and orthotopic implantation mouse models. Metastatic 
lesions in the lungs of the orthotopic implantation models at indicated time points 
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Effect of withaferin A on invasive growth 
pattern of tumor 
 
Withaferin A treatment leads to significant 
necrosis of tumor tissues in treatment group 
compared to that of control group. In control 
group, we observed tumor cell migration and 
invasion of foreign tissue space using light 
microscopic examination (Fig 3). Withaferin A 
treatment leads to ultrastructural changes in liver 
tumor tissue and non-tumor tissue. Intrahepatic 
metastasis, presence of intact tumor cells and 
invasion of tumor cells to blood vessels were 
obvious in control group. On the other hand, 
there was clear separation between tumor cells 
and liver cells and tumor endothelial cell 
disruption in the mice treated with withaferin A. 
The disruption of tumor endothelial cells might 
have contributed to inhibition of tumor 
angiogenesis. 
Effect of withaferin A on Pyk2 expression and 
tumor cell apoptosis 
 
The effect of withaferin A treatment on 
expression of the intracellular protein, Pyk2, in 
liver tumors was investigated. Western blot 
analysis demonstrated that withaferin A exposure 
significantly decreased the expression of Pyk2 in 
comparison to that in control group (Fig 4A). The 
decrease was significant at 30 µg of withaferin A 
treatment after 5 weeks. There was also 
apoptosis induction in tumor cells after treatment 
with withaferin A compared to untreated cells 
(Fig. 4B). An intracellular protein, Pyk2 is 
involved in the invasion of liver tumor and 
hindrance to treatment [25]. Pyk2 activates c-
Src/extracellular signal-regulated kinase which 
enhances cell proliferation and invasiveness of 








Fig 4: (A) Intracellular protein expression of Pyk2 in liver tumor was examined by immunostaining. (B) tumor cell 
apoptosis was compared by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling staining. 
Comparison of apoptotic tumor cells of mice with and without treatment at different time points 
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Effect of withaferin A on apoptotic signaling 
and ROCK/IP10/VEGF pathway in liver cancer 
cells and inhibition of tube formation of 
tumor endothelial cells 
 
The effect of withaferin A on apoptotic signalling 
of JHH-5 and MHCC97 cells were investigated 
by Western blot (Fig 5A). The down regulation of 
Akt signal and up regulation of BAX/P53 was 
mainly found in JHH-5 cell line. Withaferin A 
administration down-regulated the protein 
expression of ROCK, IP10, and VEGF in 
MHCC97 liver tumor cells in a dose-dependent 
manner (Fig 5B). Withaferin A also inhibited the 
tube formation ability of mouse endothelial cells 
(cell line CRL2279) in tube formation assay (Fig 
5C). 
 
Effect of withaferin A treatment on 
cytoskeletal protein actin projection 
formation 
 
The MHCC97 liver tumor cells were observed to 
give rise to obvious cytoskeletal protein actin 
projection formation (Fig 6). However, exposure 
of the MHCC97L liver tumor cells to 50 µM 
concentration of withaferin A suppressed the 






Fig 5: Western blot analysis. (A) Expression of Akt and BAX/P53 under withaferin A treatment was studied. (B) 
Protein expression of ROCK, IP10, and VEGF was compared in MHCC97L cells under withaferin A treatment. 




Fig 6: Comparison of cytoskeletal protein actin projection formation on tumor cell surface. Without withaferin A 
treatment, obvious cytoskeletal protein actin projection formation was found on MHCC97L liver tumor cell 
surface. After administration of withaferin A at concentrations of 50 μg, only a few cytoskeletal protein actin 
projection were formed on the tumor cell surface 
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The study demonstrated the effect of withaferin A 
in tumor growth and metastasis inhibition in an 
orthotopic liver tumor model. There was 
significant suppression of liver tumor growth by 
withaferin A treatment after different intervals of 
time shown by using Xenogen IVIS and higher-
resolution micro–magnetic resonance imaging. 
Withaferin A treatment also decreased the 
incidence of local and distant metastasis. The 
histological examination of control group showed 
presence of invasive tumor growth in the form of 
tumor thrombus and intrahepatic metastasis. 
However, withaferin A treated group showed 
tumor necrosis and clear demarcation between 
tumor and non-tumor tissues. Withaferin A 
treatment damaged the tumor endothelial cells 
and lead to suppression of tumor angiogenesis. 
In the control group, the electron microscopic 
examination showed long sinusoids and tumor 
cell invasion into lymphatic and blood vessels. 
The formation of sinusoids and tumor cell 
invasion into vessels clearly indicate tumor 
angiogenesis and invasiveness. 
 
To investigate the mechanism behind inhibition 
of tumor growth and angiogenesis by withaferin 
A, we monitored the expression of liver tumor 
genes IP10/ROCK/Pyk2. The western blot 
analysis revealed that withaferin A treatment 
decreased the expression of Pyk2, an 
intracellular protein involved in the invasion of 
liver tumor and hindrance to treatment [25]. 
Withaferin A also inhibited tumor-associated 
macrophage infiltration in liver tumors. Tumor 
invasion and angiogenesis is mediated by 
macrophages [9] by secreting inflammatory 
cytokines and chemokines (VEGF and MMP9) 
[10]. Withaferin A treatment inhibited the 
expression of VEGF. Obviously, liver tumor 
growth and metastasis were significantly 
suppressed by withaferin A treatment. 
 
The formation of cytoskeletal protein actin 
projection on cell surface leads to cell motility. 
Withaferin A treatment inhibited the formation of 
cytoskeletal protein actin projections on cell 
surface and intracellular protein levels of 
IP10/ROCK/VEGF in a dose-dependent manner. 
In addition, it inhibited formation of tubes in 
endothelial cells and induced apoptosis of tumor 




Withaferin A inhibits liver tumor invasion and 
angiogenesis by downregulation of cell signaling 
pathway leading to invasion and angiogenesis. It 
also inhibits tumor-associated macrophage 
infiltration leading to tumor inflammatory 
response. Therefore, withaferin A can be a 
promising candidate for the treatment of liver 
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